Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
YourWay Cannabis Brands Inc. (YOURF)
Phoenix, AZ, US
YourWay Cannabis Brands Inc. functions as a multi-state operator within the cannabis industry, conducting active sales and managing operations across Arizona and California. The company employs a diverse approach, cultivating its proprietary brands, forming alliances with other businesses, and providing white-label products. These initiatives are geared towards broadening market penetration, transforming the cannabis sector, and reimagining the interaction between consumers and cannabis brands. This organization was previously recognized as Hollister Biosciences Inc. before officially rebranding to YourWay Cannabis Brands Inc. in December of 2021. Established in 2019, the firm maintains its corporate headquarters in Phoenix, Arizona.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +900.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -90.00% | -100.00% | -99.99% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2,920.8% ★ Q3'21: +52.7% (vs Q3'20)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-12.1% Q3'21: +220.0% (vs Q3'20)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-9.3% Q3'21: +6.2% (vs Q3'20)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-5.8% Q3'21: +8.4% (vs Q3'20)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-21.3% Q3'21: +21.8% (vs Q3'20)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+68.3% Q3'21: +36.2% (vs Q3'20)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-4.83× Q3'21: 0.79× (vs Q3'20)
| Metric |
Dec 2022 actual |
Dec 2023 actual |
|---|---|---|
| Revenue |
91.73M
est.
|
122.31M
est.
|
| EBITDA |
-42.60M
est.
|
-56.80M
est.
|
| EBIT |
-48.04M
est.
|
-64.06M
est.
|
| Net Income |
—
est.
|
—
est.
|
| SGA |
51.41M
est.
|
68.54M
est.
|
| EPS | — | — |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carl A. Saling | Founder & Senior Advisor | 292.8K | male |
| Mason Cave | Chairman & Chief Executive Officer | 27.0K | male |
| Damian Solomon | Executive Vice President of Cultivation | — | male |
| Vikki Doolittle | Director of Sales | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for YOURF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
